Core Viewpoint - The company announced its semi-annual distribution plan for 2025, proposing a cash dividend of 2.5 yuan per 10 shares, totaling 1 billion yuan, which represents 53.97% of its net profit [3]. Financial Performance - The company reported a revenue of 1.769 billion yuan for the latest half-year, reflecting a year-on-year growth of 30.83% [1]. - The net profit for the same period was 186 million yuan, showing a year-on-year increase of 5.21% [1]. - The basic earnings per share were reported at 0.46 yuan [1]. Dividend Distribution History - The company has a history of dividend distributions since its listing, with the following key data: - 2025.06.30: 10 shares pay 2.5 yuan (total 1 billion yuan, dividend yield 0.61%) [1] - 2024.12.31: 10 shares pay 5 yuan (total 201 million yuan, dividend yield 1.74%) [1] - 2023.12.31: 10 shares pay 5.2 yuan (total 209 million yuan, dividend yield 1.63%) [1] - 2022.12.31: 10 shares pay 2.5 yuan (total 100 million yuan, dividend yield 0.88%) [1] - 2021.12.31: 10 shares pay 1.9 yuan (total 76 million yuan, dividend yield 0.42%) [1] - 2020.12.31: 10 shares pay 3.5 yuan (total 141 million yuan, dividend yield 0.48%) [1] - 2019.12.31: 10 shares pay 3.9 yuan (total 156 million yuan, dividend yield 0.72%) [1] Industry Comparison - In the beauty and personal care sector, the company ranks among eight firms that announced their 2025 semi-annual distribution plans, with the highest cash distribution being from Aimeike at 362 million yuan [2]. - The company's cash distribution of 1 billion yuan places it in a competitive position within the industry, with a dividend yield of 0.61% [4].

格隆汇8月22日丨丸美生物(603983.SH)披露半年报，公司上半年实现营业收入17.69亿元，同比增长 30.83%；归属于上市公司股东的净利润1.86亿元，同比增长5.21%；基本每股收益0.46元。公司拟向全 体股东每10股派发现金红利2.5元（含税）。 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-019 广东丸美生物技术股份有限公司 关于第五届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 表决情况：3 票同意，0 票反对，0 票弃权。 广东丸美生物技术股份有限公司（以下简称"公司"）第五届监事会第六次 会议于 2025 年 8 月 21 日（星期四）在公司会议室以现场结合通讯方式召开。会 议通知已于 2025 年 8 月 11 日以电子邮件、微信方式发出。本次会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席陈青梅主持。会议召开符合有关法 律、法规、部门规章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 1、审议通过了《公司 2025 年半年度报告及摘要》 公司 2025 年半年度报告及其摘要的编制和审议程序、内容、格式符合中国 证监会和上海证券交易所的有关规定；报告内容真实、客观地反映公司的财务状 况和经营成果；在提出本意见前，未发现参与 2025 年半年度报告编制和审议的 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-018 广东丸美生物技术股份有限公司 第五届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 广东丸美生物技术股份有限公司（以下简称"公司"）第五届董事会第七 次会议于 2025 年 8 月 21 日在公司会议室以现场结合通讯方式召开。会议通知已 于 2025 年 8 月 11 日以电子邮件、微信方式发出。本次会议由董事长孙怀庆主持， 应出席董事 9 名，实出席董事 9 名，监事和相关高级管理人员列席了会议。本次 董事会会议的召集、召开符合《公司法》等有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定，决议内容合法有效。 本议案已经董事会审计委员会及独立董事专门会议事先审议通过。 2、审议通过了《关于 2025 年半年度募集资金存放与使用情况的专项报告》 表决情况：9 票同意，0 票反对，0 票弃权。 具体内容详见公司同日披露的《关于 2025 年半年度募集资金存放与使用情 况的专项报告》。 3、审 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-023 广东丸美生物技术股份有限公司 2025年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 利润分配比例：每10股派发现金红利2.50元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生 变动的，拟维持每股分配比例不变，相应调整每股分配总额，并将在相关公告中 披露。 为积极合理回报投资者、共享企业价值，增强投资者获得感，广东丸美生物 技术股份有限公司（本文简称"公司"）结合经营发展实际情况以及对未来发展 的信心，综合考虑股东利益，制定了2025年半年度利润分配方案。 一、2025 年半年度利润分配方案内容 根据公司 2025 年半年度报告（未经审计），截至 2025 年 6 月 30 日，广东丸 美 生 物 技 术 股 份 有 限 公 司 母 公 司 报 表 中 期 末 未 分 配 利 润 为 人 民 币 1,517, ...

中信证券股份有限公司 关于广东丸美生物技术股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》（证监许可[2019]917 号）核准，并经上海证券交易所同意， 丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为每股 人民币 20.54 元。共计募集资金人民币 84,214.00 万元，扣除各项发行费用人民 币 5,213.80 万元后的募集资金净额为人民币 79,000.20 万元。上述募集资金到位 情况已经广东正中珠江会计师事务所（特殊普通合伙）审验，并于 2019 年 7 月 22 日出具了广会验字[2019]G16044670870 号《验资报告》。 二、募集资金管理、存放与使用情况 为规范公司募集资金管理，保护投资者的权益，根据相关法律法规以及公司 募集资金管理制度的有关规定，公司、全资子公司广州丸美生物科技有限公司、 广州禾美实业有限公司及保荐人中信证券股份有限公司与招商银行股份有限公 司广州天河支行、重庆银行股份有限公司两江分行分别签署了《募集资金专户储 存三方监管协议》《募集资金专户储存四方监管协议 ...

中信证券股份有限公司 关于广东丸美生物技术股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"）作为广东丸美生物技术股 份有限公司（以下简称"丸美生物"或"公司"）首次公开发行股票的保荐人， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》 《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，对丸美生物使用部分闲置募集资金进行现金管理事项进行了审 慎核查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》 （证监许可[2019]917 号）核准，并经上海证券交易所同意， 丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为每股 人民币 20.54 元。共计募集资金人民币 84,214.00 万元，扣除各项发行费用人民 币 5,213.80 万元后的募集资金净额为人民币 79,000.20 万元。上述募集资金到位 情 ...

Core Viewpoint - The company plans to use up to RMB 200 million of idle raised funds for cash management to improve fund utilization efficiency while ensuring that it does not affect the normal operation of fundraising projects [1][4][6]. Fundraising Basic Situation - The company raised a total of RMB 842.14 million from its initial public offering, with a net amount of RMB 790 million after deducting issuance costs of RMB 52.14 million [1]. - As of June 30, 2025, the company has used RMB 535.18 million of the raised funds, leaving a balance of RMB 254.82 million [2]. Fund Management and Usage - The company has signed agreements with banks for the management of raised funds, ensuring that funds are stored in dedicated accounts under strict supervision [2]. - The company has invested in various projects, including a cosmetics smart manufacturing factory and marketing upgrades, with total investments amounting to RMB 932.65 million [3]. Cash Management Plan - The company intends to invest the idle funds in low-risk, principal-protected financial products, excluding securities investments [4][5]. - The cash management plan is valid for twelve months from the board meeting date and allows for rolling use of the RMB 200 million limit [1][6]. Impact on Daily Operations - The cash management initiative is designed to enhance fund efficiency without affecting the normal operations of fundraising projects or the company's main business [6][8]. - The decision-making process for this cash management plan has been deemed legal and compliant with relevant regulations [7][9].

Group 1 - The company reported its main operational data for Q2 2025, including production, sales, and revenue figures for its key products [1][2] - The total production and sales figures for the main product categories are as follows: Eye products (1,417,633 produced, 1,293,001 sold, revenue of 206,219,439 yuan), Skincare products (4,321,217 produced, 4,012,166 sold, revenue of 364,708,224 yuan), Cleansing products (1,248,862 produced, 1,089,700 sold, revenue of 65,706,024 yuan), and Beauty products (2,942,370 produced, 3,173,964 sold, revenue of 268,017,038 yuan) [1] - The average selling price of eye products increased by 57.93% to 159.49 yuan due to a higher proportion of upgraded eye cream sales and a lower proportion of eye mask sales [1][2] Group 2 - The average selling price of beauty products increased by 42.78% to 84.44 yuan, attributed to optimized marketing strategies that reduced low-priced promotional items [2] - The company experienced a decrease in the prices of key raw materials, including propylene glycol and butylene glycol, which helped lower procurement costs by 2% [2] - The company implemented large-scale procurement strategies, resulting in a 10% decrease in packaging materials, a 15% decrease in tube packaging, and a 24% decrease in certain box packaging materials [2]

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the management of raised funds by Guangdong Marubi Biotechnology Co., Ltd. for the first half of 2025, highlighting the total amount raised, its usage, and the management practices in place to ensure compliance with regulations. Group 1: Fundraising Overview - The company raised a total of RMB 842,140,000.00 from the issuance of 41 million shares at RMB 20.54 per share, with net proceeds amounting to RMB 790,001,978.42 after deducting issuance costs of RMB 52,138,021.58 [1] - As of June 30, 2025, the total amount used from the raised funds was RMB 535,181,303.64, with a remaining balance of RMB 270,426,824.67 in the dedicated fundraising account [1][2] Group 2: Fund Management Practices - The company has established a dedicated fund management system in compliance with relevant regulations, including the opening of special accounts for fundraising and signing of tripartite supervision agreements with sponsors and banks [1] - The remaining balance in the fundraising account as of June 30, 2025, is distributed across various banks, with RMB 236,579,195.01 held in one account and RMB 25,918,241.87 in another [1] Group 3: Fund Usage and Projects - The company has not used idle funds for temporary working capital or to repay bank loans, nor has it changed the use of raised funds for ongoing or new projects [2][3] - The construction of the "Cosmetics Intelligent Manufacturing Factory" has been completed, but production line construction is still pending, with plans for future capacity and project arrangements based on market conditions [2][3] Group 4: Compliance and Reporting - The company has adhered to the fundraising management regulations and has not encountered any significant violations in the use of raised funds [2] - There are no changes in the implementation location or method of the fundraising projects, and no early investments or replacements have occurred [3]